AMRI awarded seven-year NIH contract

06-Jun-2018 - Last updated on 06-Jun-2018 at 16:24 GMT

(Image: BernardaSv)

AMRI will support the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies under a seven-year contract with the NIH.

The National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), awarded the contract for which the bulk of the work will be carried out at AMRI’s Albany, NY facilities.

The contract research, development and manufacturing organization (CDMO) provides services for various other NIH-funded programs, most recently for the Blueprint Neurotherapeutics Network (BPN).

AMRI also is a Dedicated Chemical Biology Consortium (CBC) Center for the NCI Experimental Therapeutics (NExT) Program, the National Center for Advancing Translational Sciences (NCATS).

Christopher Conway, senior vice president of discovery, development and analytical services and fine chemicals, at AMRI, commented in a press release:

“Our new contract with the NIH not only enhances AMRI’s ability to positively impact the health of the general public, but it also serves as a testament of our work, giving prospective customers confidence in our aptitude to solve complex scientific challenges.”

In response to a growing customer base, the company recently expanded its container closure integrity testing (CCIT) services in the European Union (EU), with further services to be added later in the year.